Compare · NVO vs SHPH
NVO vs SHPH
Side-by-side comparison of Novo Nordisk A/S (NVO) and Shuttle Pharmaceuticals Holdings Inc. (SHPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SHPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 72206.8x SHPH ($2.7M).
- Over the past year, NVO is down 45.2% and SHPH is down 90.1% - NVO leads by 44.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for SHPH).
- NVO has more recent analyst coverage (25 ratings vs 0 for SHPH).
- Company
- Novo Nordisk A/S
- Shuttle Pharmaceuticals Holdings Inc.
- Price
- $41.35-3.70%
- $0.47+4.24%
- Market cap
- $191.82B
- $2.7M
- 1M return
- -9.71%
- -32.41%
- 1Y return
- -45.22%
- -90.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SHPH
- SEC Form 3 filed by new insider Trasolini Ryan
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form D filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner